$SANION #Saniona AB Saniona - Positive topline results from Phase 2 HO trial: Tesomet achieved 6.8% weight loss in HO patients No safety concerns, however we miss satiety data Well positioned for Phase 3 in ‘21e and FDA filing ‘22e https://t.co/tbCZLSeVFx #equity #stocks https://t.co/6SHMcKKi7C